Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of +11.86% and -67.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?